The study described immune effector cell-associated enterocolitis, a gut inflammation seen after BCMA-directed CAR T cell therapy. It was a large case series of patients who developed the disorder across several treatment centres. Only 32% of patients had achieved resolution of the enterocolitis at last follow-up. Some deaths were directly attributed to complications of the disorder. As a case series it has no comparison group or incidence rate. Patient numbers and follow-up length are not reported.
Why it is interesting: BCMA-directed CAR T cell therapy is a recent form of treatment. In this series the related gut disorder was mostly unresolved at last follow-up, and some deaths followed from its complications.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.